Indonesia Urges Greater Transparency in Cross-Border Copyright Royalty Governance Before 35 Countries 
SaunaKits.com Opens Its Upstate South Carolina Showroom, Bringing Hands-On Sauna Shopping to the Southeast 
Encore Construction Shares Guidance to Help Homeowners Avoid Costly Water Damage Insurance Claim Mistakes Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity
– Phase 3 EMANATE trial to focus on rare patient populations with highest likelihood for…
Applied Molecular Transport Appoints Charlene Banard to its Board of Directors
SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq:…
Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA
FARMINGTON HILLS, Mich., April 06, 2022 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a…
Avadel Pharmaceuticals Announces Publication of Positive Secondary Endpoint Data from Pivotal Phase 3 REST-ON Trial
Once-at-bedtime FT218 demonstrated clinically meaningful improvement in assessments of disrupted nighttime sleep compared to placebo…
PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
– Initiation of Phase 1 Study Marks PepGen’s Transition to a Clinical Stage Company –…
BetterLife’s BETR-001 Demonstrates BETR-001 Anti-depressant Activity in Preclinical Models of Depression
VANCOUVER, British Columbia, April 06, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
Collegium Appoints Neil McFarlane to its Board of Directors
STOUGHTON, Mass., April 06, 2022 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…
Morphic Therapeutic Expands Leadership with Key Appointments in Clinical and Corporate Development
Dr. Brihad Abhyankar named Vice President of Clinical Development, deeply experienced GI drug development leaderAaron…
Evaxion Biotech Hosting Key Opinion Leader Webinar on Metastatic Melanoma and Personalized Cancer Immunotherapies
Tuesday, April 12th @ 12:30 pm ET COPENHAGEN, Denmark, April 06, 2022 (GLOBE NEWSWIRE) —…
Context Therapeutics® to Participate in Two April 2022 Investor Conferences
PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq:…
TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting
NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that data…
Inozyme Pharma to Present at the 21st Annual Needham Virtual Healthcare Conference
BOSTON, April 06, 2022 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical…
OpGen’s subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
Extended existing master services agreement with Sandoz, to develop digital platform for development and life…
Cognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare Conference
PURCHASE, N.Y., April 06, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical…
Clearside Biomedical to Present at the Needham Virtual Healthcare Conference
ALPHARETTA, Ga., April 06, 2022 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company…
Tonix Pharmaceuticals Announces IND Clearance for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC)
Phase 2 Clinical Trial of TNX-102 SL for the Treatment of Long COVID Expected to…
SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China
SELLAS to Receive $1 Million Milestone Payment in Second Quarter 2022 NEW YORK, April 06,…
Tilray Brands, Inc. Reports Third Quarter Fiscal Year 2022 Financial Results
Profitable Quarter Includes Net Income of $52.5 Million and Adjusted EBITDA of $10.1 Million; 12th…
BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults
First and only FDA-approved orally dissolving sublingual film for mild, moderate or severe agitation in…
Matinas BioPharma to Present at the Needham Virtual Healthcare Conference
BEDMINSTER, N.J., April 06, 2022 (GLOBE NEWSWIRE) — Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage…